The Effects of TGF-b3 Modulation on Scar Tissue Formation in the Pig

Nathan D. Schwade, PhD, James J. Fowler, MD, Joseph Leach, MD, Department of Otolaryngology - Head and Neck Surgery, University of Texas Southwestern Medical Center, Dallas, Texas

Disclosures

Wounds. 2000;12(2) 

In This Article

Results

Results of mean breaking strength for wounds tested 7 days post injury are shown in Figure 1. The greatest mean breaking strength was found in surgical wounds treated with the highest dose of neutralizing antibody to TGF-b3 (group 1). The lowest mean breaking strength was found in the highest dose of TGF-b3 isomer (group 4). The mean breaking strength of each group was then compared to each of the other groups to determine if indeed there was a dose-response curve present. Significant differences between groups was determined using a One Way ANOVA (SPSS, Chicago, IL) with the Duncan post hoc (p < 0.05). The mean breaking strength for group 1 (10ug anti-TGF-b3) was significantly higher than the means for groups 2 and 3 (1.0µg and 0.1ng anti-TGF-b3 respectively). The mean breaking strength of group 1 was significantly higher than groups 4, 5, and 6 (100ng, 10ng, and 1ng TGF-b3 isomer respectively). The mean breaking strength of group 1 was also significantly higher than the mean breaking strength of the vehicle control.

. Mean wound breaking strength versus treatment at seven days post injection. The 10mcg Anti-TGF-b3 was statistically different when compared with control.

The results of tensiometry in wounds 14 days post injury were similar to those of the 7-day wounds. The baseline differences between the 7- and 14-day animals can be attributed to variation between animals. This is why each animal was used as its own control. Group 1 demonstrated the highest mean breaking strength. The mean breaking strength of group l was significantly higher than the mean of group 3. The mean breaking strength of group 1 was also significantly higher than all groups of TGF-b3 isomer (groups 4-6). Group 1 mean breaking strength was also significantly higher than control. Breaking strength in group 1 was not found to be significantly different than group 2 (1.0µg anti TGF-b3). The mean breaking strength of all groups is shown in Figure 2.

. Mean wound breaking strength versus treatment at 14 days post injection. The 10mcg Anti-TGF-b3 was statistically different when compared with control.

Although there was a tendency towards lower breaking strengths in wounds treated with TGF-b3 isomer, no significant differences were demonstrated. Compared to control wounds, wounds treated with the highest dose of antibody to TGF-b3 and sacrificed after 7 days showed less focal acanthosis in the epidermal layers and similar crust formation. The dermis of TGF-b3-treated wounds showed less fibroplasia, less edema, and less mast-cell and giant-cell infiltration. Subcutaneous layers of TGF-b3 treated wounds showed similar fibroplasia and lymphocytic infiltrate compared to control.

Wounds treated with the highest dose of antibody to TGF-b3 (group 1) and harvested 14 days post injury showed similar focal acanthosis in the epidermal layers compared to control. However, the dermis of treated wounds showed substantially more fibroplasia than control. Similar amounts of dermal edema, mast-cell infiltrate, lymphocytic, and giant-cell infiltrate were found compared to control. The subcutaneous layers of group 1 samples showed similar amounts of fibroplasia and lymphocytic infiltrate.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....